Dong-Wook Kim

发表

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Mixed Chimerism and Immune Modulation on GVHD, Disease Recurrence and Survival after HLA-identical Marrow Transplantation for Hematologic Malignancies

H. Eom, Dong-Wook Kim, J. Lee, 2000, The Korean journal of internal medicine.

Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2011, Leukemia & lymphoma.

The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population

B. Cho, Yoo-Jin Kim, Hyo-Jin Lee, 2017, PloS one.

Efficient transduction with recombinant adenovirus in EBV-transformed B lymphoblastoid cell lines.

Soo-young Park, S. Paik, Dong-Wook Kim, 2004, Journal of biochemistry and molecular biology.

Infectious events after endoscopic procedures in patients with neutropenia and hematologic diseases

Myung-Gyu Choi, Yoo-Jin Kim, Dong-Wook Kim, 2022, Surgical Endoscopy.

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2004, Blood.

Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2012, Annals of Hematology.

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015, American journal of hematology.

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2021, Cancers.

Comparison of 2 Preparative Regimens for Stem Cell Transplantation from HLA-Matched Sibling Donors in Patients with Advanced Myelodysplastic Syndrome

Yoo-Jin Kim, Dong-Wook Kim, C. Min, 2005, International journal of hematology.

Purification of Protein Expressed from Three Different Regions of Norovirus (NoV)

Seung‐Won Park, S. Paik, J. Choi, 2008 .

Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study

Sung‐Soo Park, Dong-Wook Kim, Jongmin Lee, 2021, Cancers.

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Martin C. Müller, J. Radich, L. Ploughman, 2009, Blood.

Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2015, Thrombosis research.

Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

S. Kasner, M. Petrie, D. DeAngelo, 2022, Journal of Hematology & Oncology.

WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2007, European journal of haematology.

Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, European journal of haematology.

chronic myeloid leukemia: 2013 European LeukemiaNet recommendations for the management of

Martin C. Müller, J. Radich, R. Larson, 2013 .

Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.

T. Brümmendorf, J. Cortes, J. Lipton, 2021, Leukemia research.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Martin C. Müller, M. Baccarani, H. Kantarjian, 2018, Blood.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome‐Positive Leukemias

T. Brümmendorf, H. Kantarjian, J. Cortes, 2017, Clinical lymphoma, myeloma & leukemia.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2011, Blood.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

T. Brümmendorf, E. Vellenga, H. Kantarjian, 2014, American journal of hematology.

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Yoo-Jin Kim, Dong-Wook Kim, C. Min, 2005, Blood.

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation

Tae Woo Kim, B. Cho, Yoo-Jin Kim, 2019, Journal of Immunotherapy for Cancer.

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Martin C. Müller, H. Kantarjian, P. Rousselot, 2008 .

D. Cella, T. Masszi, Dong-Wook Kim, 2012, Leukemia research.

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

R. Larson, R. Clark, H. Kantarjian, 2010 .

An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

T. Brümmendorf, H. Kantarjian, J. Cortes, 2010 .

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

M. Baccarani, E. Vellenga, H. Kantarjian, 2012, Blood.

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

J. Radich, M. Baccarani, B. Druker, 2009 .

Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.

H. Kantarjian, J. Cortes, G. Saglio, 2011 .

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

J. Radich, R. Larson, M. Baccarani, 2011, Blood.

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Martin C. Müller, H. Kantarjian, R. Silver, 2010, Haematologica.

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

T. Clackson, M. Baccarani, J. Dipersio, 2011 .

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia

S. Agrawal, Dong-Wook Kim, H. Hsiao, 2009, International journal of hematology.

Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2020, Annals of Hematology.

Comparison of transplant‐specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, European journal of haematology.

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Sukjoong Oh, Y. Do, Joon Seong Park, 2014, Haematologica.

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

S. Voloshin, M. Mauro, N. Chaudhri, 2021 .

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2018, Haematologica.

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses

Sukjoong Oh, D. Cho, Dong-Wook Kim, 2016, Leukemia & lymphoma.

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

G. Bormans, A. Mazumder, M. Diederich, 2020, Clinical Epigenetics.

Characteristics of Cytomegalovirus Diseases among Hematopoietic Stem Cell Transplant Recipients : A 10-year Experience at an University Hospital in Korea

Yoo-Jin Kim, S. Park, Dong-Wook Kim, 2009 .

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2020, The Korean journal of internal medicine.

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

Martin C. Müller, L. Beppu, J. Radich, 2013, BMC Cancer.

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Dae Jin Jo, Sukjoong Oh, Y. Do, 2018, Cancer medicine.

Recent Advances of Management for Chronic Myeloid Leukemia

Dong-Wook Kim, 2012 .

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

Dong-Wook Kim, Soo-hyun Kim, S. Choi, 2012, International Journal of Hematology.

Dynamic change of T315I BCR‐ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

Dong-Wook Kim, Soo-hyun Kim, Dongho Kim, 2009, Hematological oncology.

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update

J. Lipton, N. Takahashi, F. Mahon, 2021, Leukemia.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

T. Brümmendorf, J. Cortes, M. Deininger, 2019, Journal of Cancer Research and Clinical Oncology.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

R. Larson, H. Kantarjian, G. Rosti, 2013, Blood.

Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent

Dong-Wook Kim, Soo-hyun Kim, Se-Eun Jang, 2009, Hematological oncology.

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.

Ji-Young Lee, Yoo-Jin Kim, Su-Hyun Kim, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

C. Chuah, Dong-Wook Kim, M. Bradley-Garelik, 2013, Leukemia & lymphoma.

Recent advances in the path toward the cure for chronic myeloid leukemia

Dong-Wook Kim, 2011, The Korean journal of hematology.

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

J. Cortes, H. Khoury, F. Guilhot, 2009, Cancer.

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

Yoo-Jin Kim, Hyeoung-Joon Kim, Dong-Wook Kim, 2009, Leukemia & lymphoma.

Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of HLA alleles with non-Hodgkin’s lymphoma in Korean population

Dong-Wook Kim, Tai-Gyu Kim, S. Roh, 2008, International journal of hematology.

Cutaneous comorbidities in patients with multiple myeloma

Dong-Wook Kim, Miri Kim, C. Min, 2018, Medicine.

Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea

J. Bae, Dong-Wook Kim, Miri Kim, 2017, Journal of the American Academy of Dermatology.

Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma.

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2012, Cytotherapy.

Viruria in Adult Hemorrhagic Cystitis Patients Following Allogeneic Hematopoietic Stem Cell Transplantation and Implication of Antiviral Treatment

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2007 .

Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.

T. Naoe, P. Ganly, L. Shih, 2010, Leukemia research.

Susceptibility of Leukemia according to the Genotype of Minor Histocompatibility Antigens in a Korean Population

Dong-Wook Kim, J. Lee, W. Min, 2007 .

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.

Dong-Wook Kim, H. Schran, Yanfeng Wang, 2011, British journal of clinical pharmacology.

Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, Blood research.

Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia

Jae-Young Kim, Dong-Wook Kim, Dae-Young Kim, 2022, Neoplasia.

A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, Blood research.

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

B. Druker, M. Heinrich, J. Cortes, 2019, The New England journal of medicine.

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

J. Cayuela, P. Szankasi, B. Druker, 2019, Cancer cell.

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

I. Flinn, R. Larson, R. Clark, 2014 .

Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.

M. Baccarani, J. Dipersio, H. Kantarjian, 2014 .

Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials

J. Cortes, F. Mahon, N. Shah, 2013 .

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Frequency and Sensitivity of BCR‐ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib‐resistant Chronic–Phase Chronic Myeloid Leukemia

Sukjoong Oh, Y. Do, H. Yhim, 2018, Clinical lymphoma, myeloma & leukemia.

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy

B. Cho, Dong-Wook Kim, Soo-hyun Kim, 2011, International journal of hematology.

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia

H. Youn, Dong-Wook Kim, Soo-hyun Kim, 2021, Cancer medicine.

Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2014, International Journal of Hematology.

inhibitors resistance or intolerance to imatinib and other tyrosine kinase Bosutinib safety and management of toxicity in leukemia patients with

T. Brümmendorf, H. Kantarjian, R. Ribeiro, 2014 .

3-year follow-up from a randomized phase 3 trial (DASISION) Early response with dasatinib or imatinib in chronic myeloid leukemia:

H. Kantarjian, J. Cortes, C. Chuah, 2014 .

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2014 .

CLINICAL TRIALS AND OBSERVATIONS Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and / or nilotinib therapy failure Running head : Bosutinib in CP CML after second-generation TKIs

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2005 .

AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth

Ita Novita Sari, T. Reya, H. Kwon, 2020, Oncogene.

Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option

S. Bae, P. Sung, Dong-Wook Kim, 2020, Frontiers in Oncology.

Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia.

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2019, Clinical lymphoma, myeloma & leukemia.

Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2019, Leukemia research.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale OPEN

R. Zadro, N. Cross, H. White, 2016 .

Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2020, American journal of hematology.

Characteristics and Survival Outcome Analysis of Extramedullary Involvement in Adult Patients With t(8;21) Acute Myeloid Leukemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Clinical lymphoma, myeloma & leukemia.

Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2012, Acta Haematologica.

Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, Annals of Hematology.

Survival benefits from reduced‐intensity conditioning in allogeneic stem cell transplantation for young lower‐risk MDS patients without significant comorbidities

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2011, European journal of haematology.

Impact of pre-transplant marrow blasts on survival of allogeneic stem cell transplantation in adult acute myeloid leukemia

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2013, International Journal of Hematology.

Comprehensive comparison of FISH, RT‐PCR, and RQ‐PCR for monitoring the BCR‐ABL gene after hematopoietic stem cell transplantation in CML

Yoo-Jin Kim, Ji-Yeon Hwang, Dong-Wook Kim, 2002, European journal of haematology.

Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2018, Cancer medicine.

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

Martin C. Müller, J. Radich, H. Kantarjian, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia

Dong-Wook Kim, Soo-hyun Kim, Seon-Young Yang, 2021, Leukemia Research.

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

Jinny Park, Sukjoong Oh, Y. Do, 2020, British journal of haematology.

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

J. Lipton, N. Takahashi, Dong-Wook Kim, 2018, Annals of Internal Medicine.

Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia

Dong-Wook Kim, Soo-hyun Kim, Seon-Young Yang, 2019, International Journal of Hematology.

Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia.

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2015, Leukemia research.

accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase

J. Radich, R. Larson, M. Gobbi, 2008 .

Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia

J. Radich, R. Larson, M. Gobbi, 2008 .

Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2014, Hematology.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013 .

Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.

I. Abraham, Dong-Wook Kim, Seongseok Yun, 2016, Clinical lymphoma, myeloma & leukemia.

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Martin C. Müller, L. Beppu, J. Radich, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal residual disease–based long‐term efficacy of reduced‐intensity conditioning versus myeloablative conditioning for adult Philadelphia‐positive acute lymphoblastic leukemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, Cancer.

Risk factors for adults with Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real‐time quantitative reverse‐transcription polymerase chain reaction

Yoo-Jin Kim, Dong-Wook Kim, J. Hwang, 2003, British journal of haematology.

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.

Dong-Wook Kim, T. Hughes, S. Branford, 2012, Blood.

Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.

Sukjoong Oh, Joon Seong Park, Hyeoung-Joon Kim, 2018, Leukemia research.

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.

B. Cho, Dong-Wook Kim, Soo-hyun Kim, 2009, Leukemia research.

The Beneficial Effect of Chronic Graft-versus-Host Disease on the Clinical Outcome of Transplantation with Fludarabine/Busulfan-Based Reduced-Intensity Conditioning for Patients with De Novo Myelodysplastic Syndrome

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2007, International journal of hematology.

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

M. Heinrich, J. Cortes, D. DeAngelo, 2016 .

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Martin C. Müller, J. Hodgson, T. Clackson, 2016, Blood.

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

J. Radich, R. Larson, M. Baccarani, 2009 .

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

R. Larson, R. Clark, H. Kantarjian, 2009 .

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Martin C. Müller, J. Dipersio, H. Kantarjian, 2008 .

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

Sukjoong Oh, Joon Seong Park, G. Lee, 2012 .

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Martin C. Müller, L. Ploughman, B. Druker, 2008 .

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis

I. Dufva, G. Martinelli, J. Cortes, 2008 .

Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Martin C. Müller, J. Radich, G. Martinelli, 2008 .

The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2010, Genes, chromosomes & cancer.

The Activating Killer Cell Immunoglobulin-Like Receptors as Important Determinants of Acute Graft-Versus Host Disease in Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia

B. Cho, Dong-Wook Kim, C. Min, 2007, Transplantation.

Successful prevention and screening strategies for COVID‐19: focus on patients with haematologic diseases

Ji-Young Lee, Yoo-Jin Kim, Sung‐Soo Park, 2020, British journal of haematology.

Clinical Characteristics and Outcomes of Posttransplant Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation in Korea

S. Park, Dong-Wook Kim, Jin-Hong Yoo, 2006, Journal of Korean medical science.

Oral Beclomethasone Dipropionate for the Treatment of Steroid-refractory Gastrointestinal Acute Graft-versus-host Disease

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2009 .

Effect of Extracorporeal Photopheresis on Steroid Resistant Acute GVHD Refractory to High Dose Steroid Treatment

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2007 .

Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation.

Dong-Wook Kim, I. Oh, Tai-Gyu Kim, 2004, Blood.

Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease.

Tae Woo Kim, B. Cho, Yoo-Jin Kim, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

MYELOID NEOPLASIA Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

R. Larson, H. Kantarjian, G. Rosti, 2013 .

chronic phase vs imatinib in patients with newly diagnosed chronic myeloid leukemia

R. Larson, H. Kantarjian, G. Rosti, 2013 .

Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.

Su-Hyun Kim, Ji-Yeon Hwang, Dong-Wook Kim, 2006, Haematologica.

Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation.

Tae Woo Kim, B. Cho, E. Choi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2014, Annals of Hematology.

The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, Annals of Hematology.

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Tae Woo Kim, B. Cho, Yoo-Jin Kim, 2016, Cancer Immunology, Immunotherapy.

Non‐myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2020, European journal of haematology.

Additional Stem Cell Therapy for Graft Failure after Allogeneic Bone Marrow Transplantation

Dong-Wook Kim, J. Lee, C. Min, 2001, Acta Haematologica.

Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2021, Bone Marrow Transplantation.

Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients.

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2021, Transplantation and cellular therapy.

Detection of the BCR-ABL Gene by Interphase Fluorescence In Situ Hybridization (iFISH) in Chronic Myelogenous Leukemia Patients after Hemopoietic Stem Cell Transplantation: The Feasibility of iFISH Monitoring of Therapeutic Response in Peripheral Blood

Yoo-Jin Kim, Dong-Wook Kim, C. Min, 2002, International journal of hematology.

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2014, European journal of haematology.

Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Risk-Adapted Preemptive Therapy for Cytomegalovirus Disease after Allogeneic Stem Cell Transplantation: A Single-Center Experience in Korea

Yoo-Jin Kim, S. Park, Dong-Wook Kim, 2005, International journal of hematology.

Allele frequencies of 15 STR loci using AmpF/STR Identifiler kit in a Korean population.

Yoo-Jin Kim, Ji-Yeon Hwang, Dong-Wook Kim, 2003, Forensic science international.

Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, European journal of haematology.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Anna L. Brown, Paul P. S. Wang, D. Thomson, 2018, Blood.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Ricardo Pasquini, Giuseppe Saglio, Andreas Hochhaus, 2010, The New England journal of medicine.

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

Martin C. Müller, J. Radich, S. Kamel‐Reid, 2008, Blood.

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

S. Redaelli, C. Gambacorti-Passerini, R. Piazza, 2015, American journal of hematology.

Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: Involvement of ER stress and DAMP release.

K. Bacharı, A. Mazumder, M. Diederich, 2018, Cancer letters.

Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A fatal case of measles pneumonia complicating an adult recipient of hemopoietic stem cell transplantation during the nationwide epidemic in Korea.

Yoo-Jin Kim, S. Park, Dong-Wook Kim, 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Roberta Spinelli, Rocco Piazza, Torsten Haferlach, 2012, Nature Genetics.

Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome

B. Cho, Yoo-Jin Kim, S. Park, 2013, Annals of Hematology.

Two cases of disseminated mucormycosis in patients following allogeneic bone marrow transplantation.

Yoo-Jin Kim, Dong-Wook Kim, Jin-Hong Yoo, 2002, Journal of Korean medical science.

SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2015, Blood research.

Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, Bone Marrow Transplantation.

The factors influencing clinical outcomes after leukapheresis in acute leukaemia

Yonggoo Kim, B. Cho, Jae‐Ho Yoon, 2021, Scientific Reports.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

M. Baccarani, J. Cortes, A. Gollerkeri, 2007, Blood.

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Blood research.

Equivalent Outcome of Autologous Stem Cell Transplantation and Reduced Intensity Conditioning Stem Cell Transplantation in Acute Myeloid Leukemia Patients with t(8;21)

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2014, Acta Haematologica.

Reduced-Intensity Conditioning Regimen Combined with Low-Dose Total Body Irradiation in the Treatment of Myelodysplastic Syndrome

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2011, Acta Haematologica.

Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B

J. Jang, S. Bae, S. Yoon, 2019, Digestive Diseases and Sciences.

Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infection in Hematopoietic Stem Cell Transplantation Recipients

B. Cho, Yoo-Jin Kim, S. Park, 2010 .

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Paul P. S. Wang, Nitesh D. Sharma, R. Rigolio, 2019, Haematologica.

Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells

H. Nakauchi, S. Stirdivant, A. Ooshima, 2015, Nature Communications.

Regulation of myeloid leukemia by the cell fate determinant Musashi

Takahiro Ito, Bryan Zimdahl, Tannishtha Reya, 2010, Nature.

MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis.

V. Kim, R. Seong, Sung-Soo Yoon, 2016, Blood.

Identification of Leukemia-Specific Fusion Gene Transcripts with a Novel Oligonucleotide Array

Seok Lee, Byoung-Don Han, Yoo-Jin Kim, 2012, Molecular Diagnosis & Therapy.

Human AQP5 Plays a Role in the Progression of Chronic Myelogenous Leukemia (CML)

C. Moon, Juna Lee, D. Sidransky, 2008, PloS one.

Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

A. Nagler, M. Deininger, M. Valsecchi, 2011, Journal of the National Cancer Institute.

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

H. Kantarjian, G. Martinelli, J. Cortes, 2017, Cancer.

Chronic myeloid leukemia in Asia

W. Au, C. Chuah, Jianxiang Wang, 2009, International journal of hematology.

Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B‐lineage acute lymphoblastic leukaemia in first or second remission

Yoo-Jin Kim, Dong-Wook Kim, C. Min, 2002, British journal of haematology.

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

J. Radich, J. Cortes, Q. Jiang, 2020, Leukemia.

Three-dimensional approach to stem cell therapy.

Dong-Wook Kim, I. Oh, Il-Hoan Oh, 2002, Journal of Korean medical science.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

J. Radich, R. Larson, M. Gobbi, 2008, Blood.

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Susan Branford, Ricardo Pasquini, Fabrizio Pane, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Hepatosplenic tuberculosis mimicking disseminated candidiasis in patients with acute leukemia

Yoo-Jin Kim, Dong-Wook Kim, C. Min, 2001, International journal of hematology.

GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia

Seung Hun Han, Joo-Yong Lee, K. Myung, 2019, Autophagy.

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

R. Larson, M. Baccarani, J. Lipton, 2007, Blood.

Polymorphisms of IL-1B, IL-1RN, IL-2, IL-4, IL-6, IL-10, and IFN-γ genes in the Korean population

Dong-Wook Kim, Chun‐Choo Kim, Tai-Gyu Kim, 2003 .

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

M. Baccarani, H. Kantarjian, J. Cortes, 2014, Blood.

Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.

Y. Do, Dong-Wook Kim, W. Lee, 2021, Clinical lymphoma, myeloma & leukemia.

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

S. Mustjoki, B. Druker, J. Cortes, 2019, Leukemia.

Optimal conditioning regimen for haplo‐identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de‐escalation study of TBI and ATG dose

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, American journal of hematology.

Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell Transplantation

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2010, Transplantation.

Low‐dose thymoglobulin for prevention of chronic graft‐versus‐host disease in transplantation from an HLA‐matched sibling donor

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2021, American journal of hematology.

High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation.

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2021, Bone Marrow Transplantation.

Megadose CD34+ Hemopoietic Stem Cell Transplantation for Patients with High Risk Acute Myeloid Leukemia Who Have No HLA Matched Donor

Yoo-Jin Kim, Dong-Wook Kim, W. Min, 2004, The Korean journal of internal medicine.

Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Infectious events after endoscopic procedures in patients with neutropenia and hematologic diseases

Myung-Gyu Choi, Yoo-Jin Kim, Dong-Wook Kim, 2022, Surgical Endoscopy.

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

Dong-Wook Kim, T. Hughes, S. Branford, 2020, Blood.

Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.

J. Lipton, N. Takahashi, F. Mahon, 2018 .

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Sukjoong Oh, Y. Do, Y. Mun, 2016, Haematologica.

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

Sukjoong Oh, Y. Do, Y. Mun, 2016, Leukemia & lymphoma.

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib

Sukjoong Oh, M. Mauro, Y. Do, 2013, American journal of hematology.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.

Polymorphisms of IL-1B, IL-1RN, IL-2, IL-4, IL-6, IL-10, and IFN-gamma genes in the Korean population.

Dong-Wook Kim, Chun‐Choo Kim, Tai-Gyu Kim, 2003, Human immunology.

Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

Susan Branford, Timothy P. Hughes, Fabrizio Pane, 2014, International Journal of Hematology.

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

P. Campbell, G. Bignell, M. Cazzola, 2015, Blood.

Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2014, Leukemia & lymphoma.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

Martin C. Müller, E. Kimby, J. Delabie, 2009, Blood.

Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2014, Hematological oncology.

BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core‐binding‐factor‐positive AML

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, European journal of haematology.

Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic Prediction Model for Second Allogeneic Stem‐Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single‐Center Report

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018, Clinical lymphoma, myeloma & leukemia.

Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts

Yoo-Jin Kim, Jae‐Ho Yoon, Dong-Wook Kim, 2016, Oncotarget.

Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2022, Blood.

Hematopoietic Stem Cell Transplantation with Using Multinational Unrelated Donors for Acute Myelogenous Leukemia

B. Cho, Dong-Wook Kim, J. Lee, 2007 .

CD161(+) T cells as predictive markers for acute graft-versus-host disease.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Circulating CD3+CD4+CD161+ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma

Tae Woo Kim, B. Cho, Yoo-Jin Kim, 2018, BioMed research international.

Low frequency of CD3+CD4+CD161+ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment

Tae Woo Kim, B. Cho, Yoo-Jin Kim, 2018, Annals of Hematology.

Circulating CD 3 + CD 4 + CD 161 + Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2018 .

Clinical significance of pre‐transplant circulating CD3+CD4+CD161+ cell frequency on the occurrence of neutropenic infections after allogeneic stem cell transplantation

Tae Woo Kim, B. Cho, Yoo-Jin Kim, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

Comparable long‐term outcomes after reduced‐intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high‐risk acute lymphoblastic leukemia in complete remission

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, American journal of hematology.

Influence of ex vivo purging with CliniMACS CD34+ selection on outcome after autologous stem cell transplantation in non‐Hodgkin lymphoma

Seung-Hwan Shin, Jae-Ho Yoon, Seok Lee, 2014, British journal of haematology.

Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia.

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Journal of Hematology & Oncology.

Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2010, International journal of hematology.

BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2016, The Korean journal of internal medicine.

Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Oncotarget.

The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2013, Blood research.

Full donor chimerism using stem-cell transplantation for tolerance induction in the human leukocyte antigen-matched liver transplant setting.

Dong-Wook Kim, W. Min, Chun‐Choo Kim, 2009, Transplantation.

A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2019, International Journal of Hematology.

Outcomes of elderly de novo acute myeloid leukemia treated by a risk‐adapted approach based on age, comorbidity, and performance status

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, American journal of hematology.

Superior transplantation outcomes of 8/8‐matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, European journal of haematology.

Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2011, European journal of haematology.

The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells

A. Ooshima, Seong-Jin Kim, K. Naka, 2020, Nature Communications.

Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high‐risk subgroup using WT1 expression in association with NPM1 and FLT3‐ITD mutations

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2015, Genes, chromosomes & cancer.

Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

Giuseppe Saglio, G. Saglio, Dong-Wook Kim, 2011, Leukemia & lymphoma.

Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2021, Blood research.

Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Yoo-Jin Kim, Ji-Yeon Hwang, Dong-Wook Kim, 2003, Blood.

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2019, Cancer medicine.

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

H. Dombret, M. Baccarani, J. Cortes, 2007 .

Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2020, Annals of Hematology.

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

I. Flinn, R. Larson, R. Clark, 2021, Leukemia.

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia according to First-Line Intravenous Immunoglobulin Response

Yoo-Jin Kim, Jae‐Ho Yoon, Dong-Wook Kim, 2022, Acta Haematologica.

Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.

Ji-Yeon Hwang, Dong-Wook Kim, Soo-hyun Kim, 2006, Translational research : the journal of laboratory and clinical medicine.

The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate.

Dong-Wook Kim, Soo-hyun Kim, Myungshin Kim, 2012, Cancer genetics.

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia

H. Youn, Dong-Wook Kim, Soo-hyun Kim, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Efficient Generation of BLCL Expressing Foreign Antigen as Antigen-presenting Cells with Recombinant Retroviruses

S. Paik, Dong-Wook Kim, Hyun-Il Cho, 2001 .

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015, British journal of haematology.

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

G. Rosti, J. Cortes, F. Guilhot, 2007 .

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

R. Larson, R. Clark, H. Kantarjian, 2012 .

Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea

Jinny Park, J. H. Lee, J. Cheong, 2022, Blood research.

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Sukjoong Oh, C. Jung, Y. Do, 2017, Clinical Cancer Research.

Results From The Korean Imatinib Discontinuation Study (KIDS): Updated Data With 14-Month Median Follow Up

Sukjoong Oh, Y. Do, Y. Mun, 2013 .

Monitoring of BCR-ABL Transcirpt Levels after Discontinuation of Imatinib Therapy in Chronic Myelogenous Leukemia Patients Achieving Complete Cytogenetic Response.

Yoo-Jin Kim, Dong-Wook Kim, J. Lee, 2004 .

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

J. Radich, M. Thornquist, G. Martinelli, 2008 .

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014 .

ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).

R. Larson, R. Clark, H. Kantarjian, 2014 .

omprehensive analysis of BCR-ABL transcript types n Korean CML patients using a newly developed ultiplex RT-PCR

Ji-Yeon Hwang, Dong-Wook Kim, Soo-hyun Kim, 2006 .

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

J. Cortes, M. Deininger, D. DeAngelo, 2018, Blood.

Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.

M. Baccarani, H. Kantarjian, F. Haluska, 2014 .

Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

H. Kantarjian, G. Martinelli, J. Cortes, 2015 .

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

R. Larson, H. Kantarjian, G. Rosti, 2011 .

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

J. Cortes, M. Deininger, G. Verhoef, 2020 .

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

S. Kapoor, J. Cortes, M. Mauro, 2021, Blood.

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

M. Heinrich, J. Cortes, M. Deininger, 2020 .

Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia

Dae Jin Jo, Sukjoong Oh, Y. Do, 2016 .

First-Line Dasatinib Plus Conventional Chemotherapy in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Interim Analysis of the Korean Prospective Phase II Study

Jin Seok Kim, H. Yhim, Yoo-Jin Kim, 2011 .

Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

T. Brümmendorf, G. Martinelli, J. Cortes, 2010 .

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study

J. Pinilla-Ibarz, Dong-Wook Kim, T. Zyczynski, 2018, Annals of Hematology.

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

J. Lipton, N. Takahashi, F. Mahon, 2016 .

Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.

J. Radich, G. Martinelli, G. Saglio, 2007 .

Comment on “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”

Dong-Wook Kim, Sung-Hyun Kim, 2015, Haematologica.

Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2018, Leukemia & lymphoma.

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Jinny Park, Sukjoong Oh, Yunsuk Choi, 2019, Blood.

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Martin C. Müller, L. Beppu, J. Radich, 2009 .

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

J. Lipton, N. Takahashi, F. Mahon, 2020 .

ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

J. Lipton, N. Takahashi, F. Mahon, 2019, Journal of Clinical Oncology.

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

H. Kantarjian, J. Cortes, M. Deininger, 2017 .

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Sukjoong Oh, Joon Seong Park, Hyeoung-Joon Kim, 2011 .

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

D. Barraco, Dong-Wook Kim, F. Nicolini, 2022, Blood.

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Dong-Wook Kim, J. Apperley, E. Abruzzese, 2018, Blood.

Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis

M. Mauro, Dong-Wook Kim, J. Apperley, 2018, Blood.

Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

J. Cortes, M. Chandy, G. Ossenkoppele, 2008 .

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Martin C. Müller, L. Beppu, J. Radich, 2009 .

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

D. Rizzieri, H. Al-Ali, Dong-Wook Kim, 2009 .

Paroxetine in the treatment of depressed patients with haematological malignancy: an open‐label study

A. Serretti, Soo-Jung Lee, C. Pae, 2004, Human psychopharmacology.

Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia

Dong-Wook Kim, S. Y. Jung, Jangik I. Lee, 2020, Journal of clinical pharmacy and therapeutics.

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

T. Clackson, H. Kantarjian, J. Cortes, 2017 .

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

A. Gnanasakthy, J. Lipton, N. Takahashi, 2016 .

Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2020, HLA.

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

G. Bormans, A. Mazumder, M. Diederich, 2020, Clinical Epigenetics.

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

H. Kantarjian, J. Cortes, G. Saglio, 2013 .

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

I. Flinn, R. Larson, R. Clark, 2019, Blood.

Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities

Yonggoo Kim, Dong-Wook Kim, Myungshin Kim, 2014, Blood research.

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Martin C. Müller, M. Baccarani, H. Kantarjian, 2015 .

Practical informativeness of short tandem repeat loci for chimerism analysis in hematopoietic stem cell transplantation.

Yonggoo Kim, Yoo-Jin Kim, Dong-Wook Kim, 2017, Clinica chimica acta; international journal of clinical chemistry.

A Case of Acute Promyelocytic Leukemia after Iodine-131 Treatment for Thyroid Cancer

B. Cho, Dong-Wook Kim, J. Lee, 2006 .

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Immune network.

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2017, Oncotarget.

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

I. Flinn, R. Larson, R. Clark, 2013 .

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

Martin C. Müller, M. Baccarani, J. Dipersio, 2012 .

Effects of Egg Yolk Antibodies Produced in Response to Different Antigenic Fractions of E. coli O157:H7 on E. coli Suppression

C. Ahn, N. Singh, Dong-Wook Kim, 2006 .

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib

E. Vellenga, H. Kantarjian, J. Cortes, 2012 .

Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015 .

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

J. Radich, R. Larson, M. Baccarani, 2013, Leukemia.

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

I. Flinn, R. Larson, H. Kantarjian, 2010 .

Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation

B. Cho, Yoo-Jin Kim, Jae‐Ho Yoon, 2013, International Journal of Hematology.

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

T. Brümmendorf, G. Martinelli, J. Cortes, 2008, Leukemia.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia

R. Larson, M. Baccarani, H. Kantarjian, 2013, Leukemia.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib : 15-month median follow-up

J. Radich, J. Dipersio, H. Kantarjian, 2009 .

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Y. Do, Hyeoung-Joon Kim, Dong-Wook Kim, 2014 .

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

D. Rizzieri, H. Al-Ali, Dong-Wook Kim, 2009 .

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Sukjoong Oh, Y. Do, Dong-Wook Kim, 2018, Blood.

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

J. Radich, H. Kantarjian, J. Lipton, 2009, Leukemia.

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

J. Radich, G. Martinelli, G. Saglio, 2007 .

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Martin C. Müller, I. Dufva, G. Martinelli, 2010 .

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation

M. Baccarani, J. Dipersio, H. Kantarjian, 2013 .

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

T. Brümmendorf, J. Cortes, M. Deininger, 2019, Journal of Cancer Research and Clinical Oncology.

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

J. Radich, R. Larson, M. Baccarani, 2011, Blood.

Martin C. Müller, H. Kantarjian, R. Silver, 2010, Haematologica.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

J. Radich, J. Dipersio, H. Kantarjian, 2009, Blood.

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Martin C. Müller, D. Colomer, J. Gabert, 2010, Blood.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib : 15-month median follow-up

J. Radich, J. Dipersio, H. Kantarjian, 2009 .

Field Trial of HFRS Vaccine in Man

Jin-Won Song, Dong-Wook Kim, L. Baek, 1989 .

Discontinuation of Imatinib Therapy in Chronic Myeloid Leukemia Patients with Sustained Complete Molecular Response4.5 (CMR4.5)

Joon Seong Park, Hyeoung-Joon Kim, Dong-Wook Kim, 2011 .

Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

C. Choi, H. Eom, H. Yhim, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Sukjoong Oh, Joon Seong Park, Hyeoung-Joon Kim, 2013 .

B. Cho, Yoo-Jin Kim, Dong-Wook Kim, 2013, American journal of hematology.

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.

J. Lipton, N. Takahashi, F. Mahon, 2016 .

Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.

Yonggoo Kim, B. Cho, Yoo-Jin Kim, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Dong-Wook Kim, Soo-hyun Kim, Sung‐Eun Lee, 2013 .

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

H. Khoury, F. Guilhot, Dong-Wook Kim, 2009, Cancer.

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .